Humanin: after the discovery. - Humanin Study

Key Findings

Humanin (24‑amino‑acid peptide) blocks neuron death caused by amyloid‑beta and Alzheimer’s genes

It also protects cerebrovascular smooth muscle cells from amyloid‑beta toxicity

Acts through a cell‑surface receptor and inhibits the JNK signaling pathway

Intracellular humanin prevents mitochondria‑mediated apoptosis by inhibiting Bax

Practical Outcomes

Humanin shows promise as a future Alzheimer’s‑targeted therapy, but there’s no actionable dosing or protocol for self‑use yet. Biohackers should view it as a research candidate and wait for clinical studies before considering supplementation.

Summary

Humanin is a tiny protein that can protect brain cells and blood‑vessel cells from the damage caused by Alzheimer’s‑related proteins. It works by binding to receptors on the cell surface and turning off harmful signaling pathways, and it can also stop cell death inside the mitochondria. However, the research so far is only in cells, with no human dosing or safety data yet.

Abstract

Humanin (HN) is a novel neuroprotective factor that consists of 24 amino acid residues. HN suppresses neuronal cell death caused by Alzheimer's disease (AD)-specific insults, including both amyloid-beta (betaAbeta) peptides and familial AD-causative genes. Cerebrovascular smooth muscle cells are also protected from Abeta toxicity by HN, suggesting that HN affects both neuronal and non-neuronal cells when they are exposed to AD-related cytotoxicity. HN peptide exerts a neuroprotective effect through the cell surface via putative receptor(s). HN activates a cellular signaling cascade that intervenes (at least) in activation of c-Jun N-terminal kinase. The highly selective effect of HN on AD-relevant cell death indicates that HN is promising for AD therapy. Additionally, a recent study showed that intracellularly overexpressed HN suppressed mitochondria-mediated apoptosis by inhibiting Bax activity.

Study Information

Provider

pubmed

Year

2004

DOI

10.1385/mn:30:3:327